Nausea in Patients Receiving Hydromorphone vs Oxycodone After Total Hip Replacement Surgery
Study Overview
Status
Status
Conditions
Conditions
Intervention / Treatment
Intervention / Treatment
Detailed Description
Study Type
Study Type
Enrollment (Actual)
Enrollment
Phase
Phase
- Phase 4
Contacts and Locations
Study Locations
-
-
Ontario
-
Toronto, Ontario, Canada, M5T 2S8
- Toronto Western Hospital
-
-
Participation Criteria
Eligibility Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
Inclusion Criteria:
- American Society of Anesthesiologists Physical Status Classification System 1-3
- Age 18-85 years
- Patients undergoing hip replacement surgery under spinal anesthesia
Exclusion Criteria:
- patient refusal
- contraindication or refusal of spinal anesthesia
- inability to provide informed consent
- history of dementia
- intolerance or allergy to oxycodone or hydromorphone
- chronic opioid use or chronic pain disorder
- pregnancy
- history of drug addiction
- history of major psychiatric illness
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: Randomized
- Interventional Model: Parallel Assignment
- Masking: Double
Number of Arms
Arms and Interventions
Participant Group / ArmParticipant Group / Arm |
Intervention / TreatmentIntervention / Treatment |
|---|---|
|
Active Comparator: Oxycodone
Patients will be prescribed oxycodone 10mg (5mg if > age 65) every 2 hours as needed for post-operative pain management in addition to tylenol 1000mg every 6 hours and celecoxib 200mg every 12 hours.
|
Patients will receive oxycodone 10mg (5mg if > 65) every 2 hours based on an equianalgesic dose calculation.
As per routine practice, the dose will be titrated according to the patient's pain at the discretion of the Acute Pain Service physician who will not be blinded to group allocation.
Other Names:
|
|
Active Comparator: Hydromorphone
Patients will be prescribed hydromorphone 2mg (1mg if > age 65) every 2 hours as needed in addition to tylenol 1000mg every 6 hours and celecoxib 200mg every 12 hours.
|
Patients will receive an initial dose of hydromorphone 2mg (1mg if > 65) every 2 hours as needed based on an equianalgesic dose calculation.
As per routine practice, the dose will be titrated according to the patient's pain at the discretion of the Acute Pain Service physician who will not be blinded to group allocation.
Other Names:
|
What is the study measuring?
Primary Outcome Measures
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
The occurrence of postoperative nausea
Time Frame: Participants will be followed for the duration of hospital stay, an expected average of 72 hours
|
The incidence and severity of nausea will be recorded twice daily up to 72 hours post-operatively
|
Participants will be followed for the duration of hospital stay, an expected average of 72 hours
|
Secondary Outcome Measures
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Daily pain scores
Time Frame: 72 hours after surgery
|
Pain scores (0-10) will be recorded twice daily until 72 hours post-operatively
|
72 hours after surgery
|
|
Incidence of opioid related itching
Time Frame: 72 hours after surgery
|
The presence or absence of the opioid related side effects will be recorded twice daily until 72 hours post-operatively
|
72 hours after surgery
|
|
Incidence of delirium
Time Frame: 72 hours after surgery
|
The presence of delirium will be recorded until 72 hours post-operatively
|
72 hours after surgery
|
|
Cumulative in-hospital opioid consumption
Time Frame: 72 hours after surgery
|
Total in-hospital opioid consumption in morphine equivalent doses will be calculated for the first 72 hours post-operatively
|
72 hours after surgery
|
|
Use of anti-nausea medications
Time Frame: 72 hours after surgery
|
The number of administrations and doses of anti-nausea medications will be evaluated until 72 hours post-operatively
|
72 hours after surgery
|
|
Cumulative drug costs per patient
Time Frame: 72 hours after surgery
|
The cumulative drug cost based on all anti-nausea and analgesic medications administered will be calculated for the first 72 hours post-operatively
|
72 hours after surgery
|
|
Post-operative admission duration
Time Frame: Total admission duration, an expected average of 72 hours
|
The number of post-operative days required for admission will be assessed.
Duration is to be an expected average of 72 hours
|
Total admission duration, an expected average of 72 hours
|
Collaborators and Investigators
Sponsor
Sponsor
Investigators
Investigators
- Principal Investigator: Richard Brull, MD, University of Toronto. University Health Network. Toronto Western Hospital.
Publications and helpful links
General Publications
- Macario A, Weinger M, Carney S, Kim A. Which clinical anesthesia outcomes are important to avoid? The perspective of patients. Anesth Analg. 1999 Sep;89(3):652-8. doi: 10.1097/00000539-199909000-00022.
- Pavlin DJ, Rapp SE, Polissar NL, Malmgren JA, Koerschgen M, Keyes H. Factors affecting discharge time in adult outpatients. Anesth Analg. 1998 Oct;87(4):816-26. doi: 10.1097/00000539-199810000-00014.
- Hartrick C, Van Hove I, Stegmann JU, Oh C, Upmalis D. Efficacy and tolerability of tapentadol immediate release and oxycodone HCl immediate release in patients awaiting primary joint replacement surgery for end-stage joint disease: a 10-day, phase III, randomized, double-blind, active- and placebo-controlled study. Clin Ther. 2009 Feb;31(2):260-71. doi: 10.1016/j.clinthera.2009.02.009.
Study record dates
Study Major Dates
Study Start (Actual)
Study Start
Primary Completion (Actual)
Primary Completion
Study Completion (Actual)
Study Completion
Study Registration Dates
First Submitted
First Submitted
First Submitted That Met QC Criteria
First Submitted That Met QC Criteria
First Posted (Estimate)
First Posted
Study Record Updates
Last Update Posted (Actual)
Last Update Posted
Last Update Submitted That Met QC Criteria
Last Update Submitted That Met QC Criteria
Last Verified
Last Verified
More Information
Terms related to this study
Keywords
Additional Relevant MeSH Terms
Other Study ID Numbers
Other Study ID Numbers
- 12-0267-AE
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.